Positively selected CD34 + hematopoietic stem cells from unrelated donors (UD-HSCT) have been successfully transplanted, but little is known about immune reconstitution in this setting. Here we report a prospective comparison of immune reconstitution in recipients of UD-HSCT and of unmanipulated bone marrow from matched sibling donors (MSD-BMT). T-cell reconstitution occurred more than 100 days later in the UD-HSCT than in the MSD-BMT group. The first T cells after UD-HSCT were almost exclusively CD45RO + HLA-DR + , whereas early-emerging T cells after MSD-BMT more frequently expressed CD62L, CD28, and CD25. In both groups, numbers of CD45RA + naive T cells increased after 180 days. After UD-HSCT, the T-cell-receptor (TCR)-repertoire was severely skewed and showed significantly reduced diversity during the first year, but only minor abnormalities were seen after MSD-BMT. TCR-diversity increased simultaneously with the number of naive T cells. In both groups, we observed transient expansions of cd T cells. B cells were reconstituted more rapidly in UD-HSCT than in MSD-BMT recipients, whereas the rapidity of NK-cell reconstitution was similar in the two groups. In summary, T-cell reconstitution was slower after UD-HSCT than after MSD-BMT because of the delayed recovery of early memory-type T cells with reduced TCR-diversity, whereas naive T-, NK-, and B cells were reconstituted similarly in the two groups.
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+ hematopoietic stem cells from unrelated donors (UD-HSCT) have been successfully transplanted, but little is known about immune reconstitution in this setting. Here we report a prospective comparison of immune reconstitution in recipients of UD-HSCT and of unmanipulated bone marrow from matched sibling donors (MSD-BMT). T-cell reconstitution occurred more than 100 days later in the UD-HSCT than in the MSD-BMT group. The first T cells after UD-HSCT were almost exclusively CD45RO + HLA-DR + , whereas early-emerging T cells after MSD-BMT more frequently expressed CD62L, CD28, and CD25. In both groups, numbers of CD45RA + naive T cells increased after 180 days. After UD-HSCT, the T-cell-receptor (TCR)-repertoire was severely skewed and showed significantly reduced diversity during the first year, but only minor abnormalities were seen after MSD-BMT. TCR-diversity increased simultaneously with the number of naive T cells. In both groups, we observed transient expansions of cd T cells. B cells were reconstituted more rapidly in UD-HSCT than in MSD-BMT recipients, whereas the rapidity of NK-cell reconstitution was similar in the two groups. In summary, T-cell reconstitution was slower after UD-HSCT than after MSD-BMT because of the delayed recovery of early memory-type T cells with reduced TCR-diversity, whereas naive T-, NK-, and B cells were reconstituted similarly in the two groups. Bone Marrow Transplantation (2003) 32, 379-390. doi:10.1038/sj.bmt.1704158 Keywords: immune reconstitution; T-cell repertoire diversity; unrelated donors; T-cell depletion; CD-34 + selection; hematopoietic stem cell transplantation Hematopoietic stem cell transplantation (HSCT) offers the only curative option for a variety of malignant and nonmalignant diseases. Unmanipulated bone marrow from a human leukocyte antigen (HLA)-matched sibling donor (MSD) has been considered the gold standard for HSCT. However, other sources have become possible with the recent introduction of peripheral blood stem cells (PBSC) mobilized by granulocyte-colony-stimulating factor (G-CSF) and the use of alternative donors (matched unrelated, mismatched related). Transplantation of PBSC is reported to significantly hasten neutrophil and platelet engraftment, 1, 2 to speed immune reconstitution, 3, 4 and to show a trend toward a lower rate of relapse. 5 However, these benefits are offset by higher rates of acute (grades II-IV) and chronic graft-versus-host disease (GvHD). 1, 5 Chronic GvHD has been identified as an important predictor of late treatment-related mortality. 6 Therefore, the reported rates of chronic GvHD after allogeneic HSCT (X55%) 7 are unacceptably high, especially in pediatric patients, whose post transplantation life expectancy is longer. One strategy used to reduce the incidence of GvHD is transplantation of positively selected CD34 + PBSC with concomitant depletion of T cells by a factor of 10 3 -10 5 . 8, 9 This strategy can reduce the incidence of acute (grades II-IV) and chronic GvHD to 13 and 3% in haploidentical transplants 10 and to 18 and 0% in unrelated-donor transplants. 1 T-cell depletion of the graft is known to impair T-cell reconstitution, 11, 12 but immune reconstitution after the transplantation of highly purified CD34 + PBSC from unrelated donors has not been studied in detail. Here we report a prospective comparison of immune reconstitution in pediatric patients who received highly purified CD34 + PBSC from unrelated donors (UD-HSCT) vs those who received a conventional bone marrow transplant from an HLA-MSD-BMT.
Methods

Patients
Between May 1998 and October 2000, 25 pediatric patients underwent HSCT at the children's hospital of the University of Tu¨bingen. Of these, 13 had no HLA-identical sibling donor and therefore received highly purified PBSCs obtained from an unrelated donor. Informed consent was obtained in all cases, in accordance with institutional regulations. Serological testing was used to determine HLA class I A and B specificity, and molecular methods were routinely used to characterize class II alleles (DRB1). Donor CD34 + PBSCs were positively selected as previously described. 9, 13 Engraftment was defined by an absolute neutrophil count 4500/ml. From day +4 to the date of engraftment, all patients received 5 mg/kg of G-CSF daily as a continuous intravenous infusion. No post transplantation GvHD prophylaxis was given. Of the 25 children, 12 received unmanipulated bone marrow from an HLA-identical sibling donor and were studied in parallel as a control group. Starting on day À3, these patients received cyclosporin A (3-5 mg/kg daily) as GvHD prophylaxis. The median duration of cyclosporin A therapy was 137 days (range 60-304 days). Surviving patients at the time of this report were followed up over a median of 1157 days (range, 604-1486 days) after transplantation in the UD-HSCT group and 1281 days (range, 928-1495days) in the MSD-BMT group. Patient characteristics and clinical outcome are listed in Table 1 .
Flow cytometry
After transplantation, subsets of peripheral blood lymphocytes were monitored by flow cytometry weekly during the first month and monthly thereafter. Anti-CD3-phycoerythrin (PE), anti-CD19-fluorescein isothiocyanate (FITC), and anti-CD16/CD56-FITC monoclonal antibodies were used to identify T-, B-, and NK-cells, respectively. B-and T-cell subsets were further characterized by a three-color flow cytometry to measure the expression of CD10, CD23, and CD40 (B cells) and CD4, CD8, TCR ab , TCR gd , CD11a, CD25, CD27, CD28, CD29, CD45RA, CD45RO, CD62L, CD69, and HLA-DR (T cells). All monoclonal antibodies were purchased from Becton Dickinson (Heidelberg, Germany).
Proliferation assays
Peripheral blood mononuclear cells (PBMCs) were isolated and resuspended at a final concentration of 2 Â 10 6 cells/ml in Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 10% human type AB serum (PAA Laboratories, Linz, Austria), 1 mmol/l l-glutamine, 100 U/ ml penicillin, and 100 mg/ml streptomycin (Gibco, Eggenstein, Germany). PBMCs (1 Â 10 5 per well) in a final volume of 200 ml were plated in 96-well flat-bottomed plates and incubated for 72 h (371C, 5% CO 2 ) in triplicate with each of five different mitogens used at the following concentrations: phytohemagglutinin (PHA) 5 mg/ml, concanavalin A (ConA) 5 mg/ml, pokeweed mitogen (PWM) 5 mg/ml, staphylococcus enterotoxin A (SEA, Sigma, Deisenhofen, Germany) 5 mg/ml, and interleukin 2 (IL-2) 10 5 U/ml (Chiron-Therapeutics, Ratingen, Germany). Cells were then pulsed with 37 kBq [ 3 H]-thymidine (Amersham Pharmacia, Freiburg, Germany) per well and, after an additional 18 h incubation (371C, 5% CO 2 ), were harvested in a Tomtec harvester (Wallac, Freiburg, Germany) as previously described.
14 Counts were enumerated on a beta scintillation counter (Microbeta Wallac, Freiburg, Germany).
Analysis of TCR repertoire
The diversity of the TCR repertoire of peripheral T cells was analyzed every 3 months after transplantation by the spectratyping method described by Gorski et al. 15 RNA was isolated and reverse-transcribed to cDNA. To ensure an equal amount of T-cell-specific cDNA for each spectratype, cDNAs were titrated against water and amplified by polymerase chain reaction (PCR) with a C bspecific primer pair. PCR products were separated by electrophoresis on 8% polyacrylamide gel. cDNAs from signals of equal intensity were used for spectratyping. 16 Titration experiments with decreasing numbers of T cells (range, 10 15, 17 the score and the size distribution were used to assess the recovery of the TCR repertoire.
Statistical analysis
The nonparametric Mann-Whitney-U-test was used for statistical comparison of the UD-HSCT and MSD-BMT groups at specific time points. A P-value o0.01 was considered to indicate a statistically significant difference between the groups. Patients experienced graft rejection and required a second transplant from the same donor after an immunologic reconditioning regimen. The proliferation of PBMCs in response to PHA, ConA, and SEA was significantly less in the UD-HSCT group than in the MSD-BMT group during the first 100 days after transplantation (Figures 2a-c) . Thereafter, no significant difference between the two groups was detectable. Proliferative responses did continue to increase in both groups, and they were equal to those of a group of healthy subjects after 1 year (Figure 2 ).
Results
T-cell reconstitution
Besides the striking disparity in T-cell numbers and function, we also observed significant phenotypic differences between the regenerating T-cell subsets of MSD-BMT and UD-HSCT recipients. As observed by other investigators, 18, 19 T cells expressing a memory phenotype (ie, expressing the CD45RO isoform of the CD45 molecule) were overrepresented during the first 6 months after transplantation in both the groups. However, while MSD-BMT recipients had a substantial number of naive T cells during the very early phase of reconstitution, before day 60 (Figure 3a and b) , almost all early-emerging T cells in UD-HSCT recipients expressed CD45RO (Figure 3a and e). These patients also had a significantly greater number of peripheral T cells expressing HLA-DR before day 180 (Po0.001) and showed a trend toward a greater number of T cells expressing CD29 (P ¼ 0.105) ( Table 2) . Conversely, in MSD-BMT recipients, more T cells expressed CD62L and CD28. However, these differences did not reach statistical significance (Table 2) . CD11a was consistently expressed on more than 95% of all T cells in both groups, and its expression did not change during the observation period. However, in UD-HSCT recipients, early appearing T cells were all CD11a high but a CD11a dull subpopulation could be observed concurrent with the appearance of naive CD8 T cells (data not shown). Interestingly, before day 60, significantly more T cells in the MSD-BMT group than in the UD-HSCT group expressed the a-chain of the IL-2 receptor (CD25) (P ¼ 0.0046). CD69 expression was not found to differ between the two groups ( Table 2) . Since the expression of CD45RA and CD45RO cannot clearly identify CD8 + T cells as naive or memory T cells, À positive cells (cytotoxic T lymphocytes, CTLs) was higher in recipients of MSD-BMT (6.2-16.6%) than in recipients of UD-HSCT (2.7-12.3%), however not statistically significant (P ¼ 0.013).
gd T cells
The majority of reconstituting T cells expressed an ab TCR. However, patients in both groups showed transient expansion of gd T cells. Between one and five patients in each groups showed an expansion of gd T cells 415% at any given time point after transplantation (seven patients in each group experienced transient gd T-cell expansion). The expansion of gd T cells lasted from 60 to 300 days. The absolute numbers of gd T cells in the peripheral blood showed two patterns of gd regeneration. The first was a slow but continuous increase in gd T-cell numbers in eight of the 13 patients in the UD-HSCT group and four of the 12 patients in the MSD-BMT group (Figure 4a and c) . The second was marked by a rapid but temporary expansion of gd T cells in five patients in the UD-HSCT group and eight patients in the MSD-BMT group. Expansion of gd T cells was not seen in the UD-HSCT group before day 200, but occurred immediately after transplantation in the MSD-BMT group (Figure 4b and c) . These periods of gd T-cell expansion did not coincide with episodes of graft rejection or GvHD.
TCR-repertoire
Since numbers of peripheral T cells provide no information about the diversity of the ab T-cell pool, we prospectively analyzed T-cell-receptor-(TCR) repertoire complexity by complementarity-determining region 3 (CDR3)-size spectratyping. 15, 16 Recipients of unmanipulated bone marrow showed an almost complete TCR repertoire throughout the observation period, with a median of five to six bands per Vb family and only minor skewing in some Vb families (Figure 5a and c) . In contrast, recipients of UD-HSCT had a severely skewed TCR repertoire with reduced complexity, with a median of only two bands per Vb family until day 200 (Figure 5a and b) . TCR repertoire diversity improved after day 200 and was comparable to that of MSD-BMT recipients after 1 year. The difference between the two groups in TCR repertoire diversity was statistically significant during the entire first year after transplantation (Po0.01, Figure 5a ). Figure 5b and c depicts one representative example from each group at approximately day 100 after transplantation.
B-cell reconstitution
Unlike T cells, peripheral B cells reconstituted faster in the UD-HSCT group than in the MSD-BMT group. The median time required to reach CD19 + cell count 4100/ml was 69 days (range, 49-105 days) in the UD-HSCT group and 176 days (range, 66-462 days) in the MSD-BMT group (P ¼ 0.001). The number of peripheral B cells remained lower in the MSD-BMT group until day 120 after transplantation (P ¼ 0.001) (Figure 1c ). In the latter group, one patient (Patient 25) failed to reach a CD19 + count4100/ml. This patient died of pulmonary aspergillosis on day 242 after transplantation.
CD10 expression was high in early reconstituting B cells and declined in both groups at comparable rates. The groups did not differ significantly at any time point in the expression of CD10, CD23, or CD40. B cells in both the groups expressed CD40 and CD23 increasingly with time (Table 3) .
Despite the faster B-cell reconstitution of UD-HSCT recipients, their PBMC did not show an increased proliferative response to PWM. Like the proliferative responses to T-cell mitogens, the response to PWM was During the first year after transplantation, PBMCs from recipients of MSD-BMT (light gray), recipients of UD-HSCT (dark gray), and healthy control subjects (black) were stimulated in triplicate with (a) PHA, (b) ConA, (c) staphylococcus enterotoxin A, (d) PWM, and (e) interleukin-2 as described in Materials and methods. Results are given as difference in counts per minute (Dcpm), that is, mean of sample counts minus mean of background counts. During the first 100 days, PBMCs of MSD-BMT recipients showed a significantly greater proliferative response to PHA, ConA, SEA, and PWM than did those of UD-HSCT recipients. At all later time points and in response to IL-2, no significant difference between the two patient groups could be detected.
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significantly smaller in UD-HSCT than in MSD-BMT recipients during the first 100 days (P ¼ 0.002) and was comparable thereafter. Neither group's values equaled those of the healthy subjects at the end of 1 year (Figure 2 ). Serum IgG concentration after cessation of IgG supplementation (around day 200) was similar in UD-HSCT and MSD-BMT recipients during the first year after transplantation, but was significantly lower in UD-HSCT recipients thereafter (P ¼ 0.001). However, none of the UD-HSCT recipients required further IgG supplementation. Levels of IgM and IgA were not significantly different in the two groups at any time point (Table 4) . In UD-HSCT recipients, CD45RA was not expressed before day 120, whereas in MSD-BMT recipients, CD45RA + T cells were detectable before day 60. Around day 180, an increase in the expression of CD45RA was observed in both patient groups, reflecting thymic recovery. By the end of the first year posttransplantation, a stable equilibrium between naive and memory T cells was reached.
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NK-cell reconstitution
Peripheral NK-cell counts were higher in recipients of UD-HSCT; however, this difference did not reach statistical significance. Median NK-cell counts in the early post transplantation period (day 30) were 180/ml (range, 69-959/ ml) in the UD-HSCT group and 120/ml (range, 24-694/ml) in the MSD-BMT group (P ¼ 0.310). Unlike T-and B-cell mitogens, IL-2, a cytokine known to induce NK-cell activation and proliferation, did not induce a significantly different proliferative response in the two groups at any time point (Figure 2e ).
Discussion
Immune reconstitution after autologous or allogeneic stem cell transplantation [21] [22] [23] [24] and after chemotherapy-induced myelosuppression 25 has been extensively studied. Innate immunity (granulocytes, monocytes, NK cells) are generally assumed to recover within the first 1 or 2 months post transplantation, whereas reconstitution of antigen-specific immunity (T-and B cells) takes considerably longer. 21 Reconstitution of antigen-specific T cells is of particular importance for the host's antitumor and antiviral defenses. T-cell regeneration can occur via either of two major pathways: (1) peripheral expansion of donor T cells 18, 26 and (2) thymus dependent de novo generation of naive T cells. 27, 28 The first mechanism is usually predominant in the first months post transplantation. It restores a T-cell immunity that is limited in diversity 17 ,29 yet can induce strong alloreactive immune responses like GvH or GvL reactions and can usually protect the patient from overwhelming infections. In children and adults with residual thymic function, the second pathway will complete the T-cell repertoire after approximately 6 months by adding newly generated naive T cells with broad antigen specificity. 27, 30 Manipulation of the graft to prevent serious complications can affect immune reconstitution. Removal of B cells helps to prevent EBV-induced lymphoproliferative disease. 31 In vivo or ex vivo T-cell depletion can effectively reduce the incidence and severity of GvHD, 1, 10 but it may significantly delay T-cell reconstitution. 11, 12 A number of different in vivo [32] [33] [34] [35] and ex vivo 8 strategies have been used to deplete T cells from the graft. In our study, T cells were rigorously depleted (reduced by a factor of 10 + hematopoietic progenitor cells with the CliniMACS-system. 9 This profound T-cell Immune reconstitution in pediatric UD-HSCT vs MSD-BMT M Eyrich et al depletion has previously been used with success in megadose transplantation of haploidentical PBSC, 10, 13 resulting in a surprisingly fast immune reconstitution in pediatric recipients. 36 In the present study we wanted to investigate how positive selection affects immune reconstitution in pediatric UD-HSCT in comparison to transplantation of unmanipulated bone marrow from an HLA-matched sibling donor. The latter approach is the treatment of choice when an HLA-matched sibling donor is available, and immune reconstitution in this setting is well characterized. 21, 22, 37, 38 Both patient groups received transplants during the same study period, received the same supportive care, and were studied in a prospective fashion.
We found that T-cell recovery was significantly (more than 100 days) slower in recipients of UD-HSCT than in MSD-BMT recipients. Interestingly, the recovery of both CD4 + and CD8 + T cells was delayed. The slower T-cell recovery was mirrored by lower proliferative responses to PHA, ConA, and SEA before day 100, in part reflecting the smaller number of peripheral T cells during this period. Although the number of fatal infectious complications did not differ between the two groups in this study, the 140-day numerical and functional T-cell deficiency in the UD-HSCT group is likely to cause a higher rate of infectious complications. This difference may become apparent only in a larger cohort of patients. 39 A closer look at the T-cell compartment offered insights into the mechanisms operating. Although memory-type T cells predominated in the early post transplantation phase, as previously reported, 18, 19 significant differences were observed between the two groups. In MSD-BMT recipients, the peripheral T-cell compartment contained many naive CD45RA + T cells from the very beginning (Figure 3a  and b) . These naive T cells were likely to have been transferred from the donor, since thymic function reportedly takes 3-6 months to recover after transplantation. 27, 40 In adult patients receiving PBSC grafts that are not T-cell depleted, the graft is considered to be the main source of naive T cells for a prolonged period. 4 In UD-HSCT recipients, unlike MSD-BMT recipients, early-appearing T cells expressed a memory phenotype (CD45RO + CD4 + or CD27 + CD8 + , Figure 3a and e). The number of HLA-DR and CD45RO single positive T cells was significantly higher in the UD-HSCT group, whereas the number of CD62L + and CD28 + T cells was lower (Table 2) . This finding and the high level of CD11a expression identify these T cells as being highly activated and primed T cells. 20, 41 However, the high expression of CD11a, CD45RO, and HLA-DR does not necessarily imply that these T cells were alloreactive, as the incidence of GvHD was not higher in UD-HSCT recipients in this study, even without post transplantation immunosuppression. To the contrary, the significantly greater expression of CD25 in the MSD-BMT recipients before day 60 (Table 2) suggests that their T cells were potentially alloreactive. The depletion of CD25 + T cells in HLA-matched and -mismatched situations resulted in reduced alloreactivity while preserving antileukemic and antiviral responses. 42, 43 We have observed the complete absence of naive T cells in the early period after transplantation of positively selected CD34 + haploidentical PBSC. 36 This observation can be explained in part by the small number of cotransplanted T cells. Another mechanism that could explain this phenomenon is homeostatic proliferation of naive T cells with a subsequent switch of phenotype. Generation of functional CD4 + and CD8 + memory T cells after encounter with endogenous antigen, which has been recently described, 44, 45 may occur in the setting of extreme lymphopenia after transplantation of highly purified CD34 + PBSC. The assessment of TCR repertoire complexity by CDR3-size spectratyping is an important tool for quantifying Tcell reconstitution after transplantation. 15, 37 In UD-HSCT recipients, TCR repertoire diversity was very low during the Po0.01. IgG concentration after the first year was significantly lower in UD-HSCT than in MSD-BMT recipients.
Immune reconstitution in pediatric UD-HSCT vs MSD-BMT M Eyrich et al 387 first 200 days post transplantation and gradually increased thereafter, whereas MSD-BMT recipients showed only minor abnormalities in the TCR repertoire ( Figure 5 ). Because early-appearing T cells are considered to be the progeny of transplanted T-cell precursor, 29 the severely skewed repertoire was the direct consequence of positive selection of CD34 + cells and the resultant depletion of T-cell precursors. The increase in TCR repertoire diversity occurred simultaneously with the appearance of naive T cells in the periphery, consistent with the finding that thymic function after transplantation is directly related to TCR repertoire diversity. 46 This finding underlines the importance of residual thymic function for complete recovery of TCR repertoire diversity, especially after T-cell depletion. 30 Another T-cell population that provides a defense against infection after transplantation is gd T cells. In both groups (in 14 of 25 patients), we observed transient expansion of gd T cells lasting 60-300 days. Some investigators have proposed that gd expansion after transplantation is better explained by the frequency of intercurrent infection than by GvHD. 47 The predominant mechanism of gd reconstitution seems to be peripheral expansion of donor gd clones, which can persist for more than 1.5 years after transplantation. 48 Unlike ab T cells, gd T cells can reconstitute via an alternative, thymusindependant pathway. 49, 50 However, the precise regulatory and cytotoxic functions of gd T cells after transplantation are not fully understood, and further investigation is required to define the role and importance of gd T cells as potential targets for post transplantation immunotherapy.
Alloreactive NK cells potently facilitate engraftment 51 and exert antileukemic activity 52 while protecting the patient from GvHD, especially when donor and patient have mismatched killer inhibitor receptor (KIR) epitopes. 53 Infusion of alloreactive NK cells can obviate the need for high-intensity conditioning. 52 NK cell recovery in this study was rapid in both the groups and the proliferative responses to IL-2 were similar. Since alloreactive NK cells appear to exert a beneficial effect only when the KIR epitope is mismatched, it remains to be determined whether recipients of UD-HSCT can benefit from this rapidly regenerating cell population.
B-cell recovery was more rapid in recipients of UD-HSCT, who also showed slightly higher expression of CD10 before day 120. Therefore, the early appearing B cells in the UD-HSCT group were generated de novo in the host. However, the faster regeneration of B cells was not accompanied by stronger proliferative responses to PWM before day 100, probably owing to the small number of peripheral T cells, which can provide T-cell support during this period. After immunoglobulin supplementation was discontinued at about day 200, all surviving patients in both groups (except patient 2, who received immunosuppression to control autoimmune hemolytic anemia) were able to maintain sufficient levels of IgG, IgM, and IgA, although IgG concentration was higher in MSD-BMT recipients after the first post transplantation year.
Interestingly, reconstitution of peripheral T-cell numbers took approximately 60 days longer in recipients of CD34 + UD-HSCT than in recipients of CD34 + haploidentical
HSCT. 36 The median number of graft-contaminating T cells did not differ significantly in the UD-HSCT and haplo groups (median 6.5 Â 10 3 and 11.6 Â 10 3 /kg). However, recipients of haploidentical HSCT received significantly higher doses of CD34 + PBSC (P ¼ 0.002) in order to overcome HLA barriers. 54 If we assume that earlyappearing memory T cells are the progeny of donor T cells, then early memory T cells should recover equally rapid in the two groups. The beneficial effect of higher stem-cell doses appears to suggests that transplantation of large numbers of CD34 + PBSC supports T-cell reconstitution. 55 The mechanism of such an effect is not fully understood, and further investigation is warranted.
In summary, transplantation of positively selected CD34 + PBSC from unrelated donors resulted in successful engraftment followed by a fast hematologic recovery. However, reconstitution of early-appearing, highly activated T cells required more than 100 days longer in this group than in the MSD-BMT group, and TCR repertoire diversity was severely restricted in the early memory T-cell pool. In both patient groups, reconstitution of naive T cells was observed after about 6 months, at which time the limited TCR repertoire in UD-HSCT recipients acquired diversity. B-cell recovery was significantly faster in UD-HSCT recipients, whereas NK-cell reconstitution was comparable in the two groups.
Further studies are needed to discover whether these differences in immune reconstitution will counterbalance the beneficial effect of CD34 seletion in reducing GvHD. Immune reconstitution after allogeneic HSCT, especially after T-cell depletion or CD34 + -cell selection, clearly needs further improvement. This may be achieved in several ways. First, the frequency of T-cell precursors in the CD34 + -selected graft can be increased by targeted addback of defined numbers of T cells. This strategy may hasten the expansion of peripheral T cells and expand the TCR repertoire of early-appearing memory T cells. Depletion of CD25 + T cells with alloreactive potential may lower the risk of GvHD in these cases. 42, 43 Second, administration of a larger number of CD34 + PBSC, as in haploidentical transplantation, may enhance immune reconstitution. Third, the generation of naive T cells may be accelerated by administering T-cell-specific cytokines such as IL-7 56, 57 or by improving the interaction between thymocytes and thymic epithelial cells by administering keratinocyte growth factor. 58 
